Compare Stocks: IPCIF, MCUJF, LPCN, and BFRI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$1.15 -1.7%	$1.31	$0.55 ▼ $1.66	$17.38M	0.83	791,188 shs	264,747 shs
IPCIF Intellipharmaceutics International		$0.00	$0.00 ▼ $0.15	$4.96M	1.53	12,042 shs	N/A
LPCN Lipocine	$2.12 -1.9%	$2.18	$1.81 ▼ $12.37	$17.81M	0.47	32,530 shs	90,862 shs
MCUJF Medicure	$1.91 +0.6%	$1.25	$0.67 ▼ $1.93	$19.83M	1.15	15,629 shs	2,800 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	-1.71%	-4.96%	-21.23%	+21.49%	+20.79%
IPCIF Intellipharmaceutics International	0.00%	0.00%	0.00%	0.00%	0.00%
LPCN Lipocine	-1.85%	-1.85%	+2.91%	-10.92%	-23.19%
MCUJF Medicure	+0.56%	+3.28%	+117.36%	+183.22%	+134.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$1.15 -1.7%	$1.31	$0.55 ▼ $1.66	$17.38M	0.83	791,188 shs	264,747 shs
IPCIF Intellipharmaceutics International		$0.00	$0.00 ▼ $0.15	$4.96M	1.53	12,042 shs	N/A
LPCN Lipocine	$2.12 -1.9%	$2.18	$1.81 ▼ $12.37	$17.81M	0.47	32,530 shs	90,862 shs
MCUJF Medicure	$1.91 +0.6%	$1.25	$0.67 ▼ $1.93	$19.83M	1.15	15,629 shs	2,800 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	-1.71%	-4.96%	-21.23%	+21.49%	+20.79%
IPCIF Intellipharmaceutics International	0.00%	0.00%	0.00%	0.00%	0.00%
LPCN Lipocine	-1.85%	-1.85%	+2.91%	-10.92%	-23.19%
MCUJF Medicure	+0.56%	+3.28%	+117.36%	+183.22%	+134.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	2.00	Hold	N/A	N/A
IPCIF Intellipharmaceutics International	0.00	N/A	N/A	N/A
LPCN Lipocine	2.00	Hold	$4.00	88.68% Upside
MCUJF Medicure	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IPCIF, MCUJF, LPCN, and BFRI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	LPCN Lipocine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/21/2026	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$4.00
9/3/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/15/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/29/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$41.71M	0.41	N/A	N/A	$0.90 per share	1.28
IPCIF Intellipharmaceutics International	$660K	0.00	N/A	N/A	($0.32) per share	0.00
LPCN Lipocine	$1.98M	8.82	N/A	N/A	$2.61 per share	0.81
MCUJF Medicure	$20.65M	0.97	N/A	N/A	$0.89 per share	2.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$10.54M	-$0.45	N/A	N/A	N/A	-13.78%	-145.81%	-31.30%	11/11/2026 (Estimated)
IPCIF Intellipharmaceutics International	-$2.89M	-$0.16	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	-$9.63M	-$1.79	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	11/5/2026 (Estimated)
MCUJF Medicure	-$5.08M	-$0.51	N/A	N/A	N/A	-23.14%	-54.55%	-30.42%	11/19/2026 (Estimated)

Latest IPCIF, MCUJF, LPCN, and BFRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	MCUJF Medicure	-$0.0474	-$0.10	-$0.0526	-$0.10	$2.45 million	$5.36 million
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
IPCIF Intellipharmaceutics International	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
MCUJF Medicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	0.78	1.18	1.08
IPCIF Intellipharmaceutics International	N/A	N/A	N/A
LPCN Lipocine	N/A	11.48	11.48
MCUJF Medicure	0.02	0.97	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
IPCIF Intellipharmaceutics International	N/A
LPCN Lipocine	9.11%
MCUJF Medicure	N/A

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	8.10%
IPCIF Intellipharmaceutics International	1.76%
LPCN Lipocine	4.69%
MCUJF Medicure	12.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	94	14.85 million	13.65 million	No Data
IPCIF Intellipharmaceutics International	10	33.09 million	32.51 million	Not Optionable
LPCN Lipocine	14	8.24 million	7.86 million	No Data
MCUJF Medicure	N/A	10.44 million	9.09 million	Not Optionable

IPCIF, MCUJF, LPCN, and BFRI Headlines

Recent News About These Companies

Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress

September 8, 2026 | accessnewswire.comA

Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

August 14, 2026 | accessnewswire.comA

Medicure Announces CFO Change

July 3, 2026 | accessnewswire.comA

Medicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...

May 26, 2026 | finance.yahoo.com

Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call

May 21, 2026 | finanznachrichten.de

Medicure Announces AGM Results and Appointment of New Director

May 21, 2026 | accessnewswire.comA

Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call

May 21, 2026 | accessnewswire.comA

Medicure Inc (MCUJF) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Rising Losses

April 28, 2026 | finance.yahoo.com

Medicure Announces Resignation of President and Chief Operating Officer

April 17, 2026 | accessnewswire.comA

Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended September 30, 2025

November 20, 2025 | finanznachrichten.de

Medicure Reports Financial Results for Quarter Ended September 30, 2025

November 19, 2025 | accessnewswire.comA

Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025

November 13, 2025 | accessnewswire.comA

Medicure Reports Financial Results for Quarter Ended June 30, 2025

August 20, 2025 | accessnewswire.comA

Medicure to Present Financial Results on August 21, 2025 Call at 8:30 am ET for Quarter Ended June 30, 2025

August 18, 2025 | accessnewswire.comA

Medicure Completes Acquisition of West Olympia Pharmacy

June 17, 2025 | tipranks.com

Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia Pharmacy

June 17, 2025 | accessnewswire.comA

Medicure reports stable intangible assets in Q1 filing

May 23, 2025 | investing.com

Medicure: Q1 Earnings Snapshot

May 21, 2025 | michigansthumb.comM

Medicure Reports Financial Results for Quarter Ended March 31, 2025 and Annual General Meeting Director Election Results

May 21, 2025 | accessnewswire.comA

Medicure Inc. (MCUJF) Q4 2024 Earnings Call Transcript

April 30, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPCIF, MCUJF, LPCN, and BFRI Company Descriptions

Biofrontera NASDAQ:BFRI

$1.15 -0.02 (-1.71%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.17 +0.02 (+1.74%)

As of 09:15 AM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Intellipharmaceutics International OTCMKTS:IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

Lipocine NASDAQ:LPCN

$2.12 -0.04 (-1.85%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.13 +0.01 (+0.71%)

As of 09:14 AM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Medicure OTCMKTS:MCUJF

$1.91 +0.01 (+0.56%)

As of 09/23/2026 03:59 PM Eastern

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPCIF, MCUJF, LPCN, and BFRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPCIF, MCUJF, LPCN, and BFRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPCIF, MCUJF, LPCN, and BFRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPCIF, MCUJF, LPCN, and BFRI Company Descriptions

Biofrontera NASDAQ:BFRI

Intellipharmaceutics International OTCMKTS:IPCIF

Lipocine NASDAQ:LPCN

Medicure OTCMKTS:MCUJF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPCIF, MCUJF, LPCN, and BFRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPCIF, MCUJF, LPCN, and BFRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPCIF, MCUJF, LPCN, and BFRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPCIF, MCUJF, LPCN, and BFRI Company Descriptions

Biofrontera NASDAQ:BFRI

Intellipharmaceutics International OTCMKTS:IPCIF

Lipocine NASDAQ:LPCN

Medicure OTCMKTS:MCUJF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools